My Cart

Granzyme B

Granzyme B Product List

  • Product Category

    Kits (2)Protein (1)

  • Product Status

    Launched (2)In Research (1)

  • Species

    Human (3)

  • Tag

    - (2)Tag Free (1)

  • Conjugate

    - (2)Unconjugated (1)

Granzyme B Background

Granzyme B (GZMB) is also known as Cathepsin G-like 1 (CTSGL1), Cytotoxic T-lymphocyte proteinase 2 (Lymphocyte protease), Fragmentin-2, Granzyme-2, Human lymphocyte protein (HLP), SECT, CGL1, CSPB, CTLA1, GRB, which belongs to the peptidase S1 family. Granzyme subfamily. GZMB / CTSGL1 contains 1 peptidase S1 domain. The catalytic activity of Granzyme B is “Preferential cleavage: -Asp-|-Xaa- >> -Asn-|-Xaa- > -Met-|-Xaa-, -Ser-|-Xaa-“, and is Inactivated by the serine protease inhibitor diisopropyl fluorophosphates. GZMB is necessary for target cell lysis in cell-mediated immune responses. It cleaves after Asp. GZMB seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution and cleaves caspase-3, -7, -9 and 10 to give rise to active enzymes mediating apoptosis.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
DR-01DR-01Phase 2 ClinicalDren Bio IncLeukemia; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, T-Cell; Bacterial Infections; Autoimmune Diseases of the Nervous System; Leukemia, Large Granular Lymphocytic
Details
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland